Treatment of recalcitrant tendinopathy remains a clinical challenge for physicians without a minimally invasive treatment option that can consistently provide patients with a long-term relief from chronic pain and ability to return to function. Surgical debridement of degenerative tendon tissue has long been the standard of care to treat degenerative tendon pathology once all conservative or minimally invasive treatment options have failed. Ultrasound guided tenotomy is an emerging treatment option with the potential to address the underlying degenerative, diseased tissue, by selectively resecting and removing the tissue in a minimally invasive manner. Additionally, with the availability of in-office diagnostic ultrasound imaging, physicians now have an opportunity to evaluate and classify underlying tendon pathology during a clinical exam. This study is to evaluate outcomes in patients presenting with a clinical history of recalcitrant tendinopathy with confirmed diagnosis of degenerative tendinosis using diagnostic ultrasound imaging or MRI.
Study Type
OBSERVATIONAL
Enrollment
600
During the procedure, the TenJet device will remove degenerative tendinopathic tissue using pressurized saline without causing harm to the healthy tendon fibers.
The TenJet system will be used during surgery to remove the damaged tissue from the joint
Standford Medicine
Redwood City, California, United States
Cleveland Clinic
Coral Springs, Florida, United States
Ochsner Health
Baton Rouge, Louisiana, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Cleveland Clinic
Lorain, Ohio, United States
Penn Highlands Orthopedics and Sports Medicine
Clarion, Pennsylvania, United States
Rothman Orthopaedic Institute
Philadelphia, Pennsylvania, United States
Pain reduction
Using the Visual Analog Scale for Pain (VAS) participants will be asked to report their pain score after surgery
Time frame: 2 years
Return to function (Elbow #1)
This will be measured in participants undergoing treatment for Elbow Tendinopathy using the Mayo Elbow Performance Score (MEPS)
Time frame: 2 years
Return to function (Elbow #2)
This will be measured in participants undergoing treatment for Elbow Tendinopathy using the Patient-Rated Tennis Elbow Evaluation (PRTEE) survey
Time frame: 2 years
Return to function (Elbow #3)
This will be measured in participants undergoing treatment for Elbow Tendinopathy using the Quick Disability Arm, Shoulder and Hand (QDASH) survey
Time frame: 2 years
Return to function (All cohorts)
This will be measured in participants undergoing treatment for Elbow, Hip and Shoulder Tendinopathy using the Short Form Health Survey (SF-12) survey
Time frame: 2 years
Return to Function (Hip)
This will be measured in participants undergoing treatment for Hip Tendinopathy using the Victorian Institute of Sport Assessment-Gluteal Questionnaire (VISA-G) survey
Time frame: 2 years
Return to Function (Shoulder)
This will be measured in participants undergoing treatment for Shoulder Tendinopathy using the American Shoulder \& Elbow Score (ASES) survey
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.